Artículo
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Autor/es | Marchesi, Francesco
Salmanton-García, Jon Emarah, Ziad Piukovics, Klára Nucci, Marcio López-García, Alberto Espigado Tocino, Ildefonso Pagano, Livio |
Departamento | Universidad de Sevilla. Instituto de Biomedicina de Sevilla (IBIS) Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2023-01 |
Fecha de depósito | 2024-01-31 |
Publicado en |
|
Resumen | Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The
optimal management of AML patients with COVID-19 has not been established. Our multicenter study included ... Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible. |
Cita | Marchesi, F., Salmanton-García, J., Emarah, Z., Piukovics, K., Nucci, M., López-García, A.,...,Pagano, L. (2023). COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 108 (1), 22-33. https://doi.org/10.3324/haematol.2022.280847. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
COVID-19...pdf | 770.4Kb | [PDF] | Ver/ | |